Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etrasimod - Pfizer

Drug Profile

Etrasimod - Pfizer

Alternative Names: APD-334; Etrasimod arginine - Pfizer; PF-07915503; VELSIPITY

Latest Information Update: 30 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arena Pharmaceuticals
  • Developer Arena Pharmaceuticals; Everest Medicines; Pfizer
  • Class 3-ring heterocyclic compounds; Acetic acids; Amino acids; Anti-inflammatories; Benzene derivatives; Cyclopentanes; Ethers; Fluorinated hydrocarbons; Indoles; Skin disorder therapies; Small molecules
  • Mechanism of Action Sphingosine 1 phosphate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Eosinophilic oesophagitis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ulcerative colitis
  • Phase II/III Atopic dermatitis; Crohn's disease
  • Phase II Eosinophilic oesophagitis
  • Discontinued Alopecia areata; Inflammatory bowel diseases; Primary biliary cirrhosis; Pyoderma gangrenosum

Most Recent Events

  • 30 May 2024 Pfizer terminates phase II/III clinical trials in Atopic dermatitis (Treatment-resistant) in USA, Canada, Czech Republic, Poland (PO), due to efficacy reasons only and is not due to any safety concerns (NCT05732454)
  • 24 Apr 2024 Pfizer granted a Notice of Compliance (NOC) from Health Canada for VELSIPITY™ in Ulcerative Colitis (UC) in Canada
  • 14 Mar 2024 Launched for Ulcerative colitis in USA (PO), before March 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top